Platelet-derived growth factor stimulates phospholipase C-γ1, extracellular signal-regulated kinase, and arachidonic acid release in rat myometrial cells:: Contribution to cyclic 3′,5′-adenosine monophosphate production and effect on cell proliferation

被引:20
作者
Boulven, I [1 ]
Palmier, B [1 ]
Robin, P [1 ]
Vacher, M [1 ]
Harbon, S [1 ]
Leiber, D [1 ]
机构
[1] Univ Paris 11, CNRS, UMR 8619, Lab Signalisat & Regulat Cellulaires, F-91405 Orsay, France
关键词
cyclic adenosine monophosphate; growth factors; kinases; signal transduction; uterus;
D O I
10.1095/biolreprod65.2.496
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In the present study, we examined downstream signaling events that followed exposure of cultured rat myometrial cells to platelet-derived growth factor (PDGF) and their effect on cell proliferation. PDGF-BB induced tyrosine phosphorylation of PDGF-beta receptors and increased inositol trisphosphate production via the tyrosine phosphorylation of phospholipase (PL)C-gamma1. PDGF-BB also increased cAMP synthesis. This increase was potentiated by forskolin and reduced by indomethacin, a cyclooxygenase inhibitor, reflecting a Gs protein-mediated process via prostaglandin biosynthesis. The prostaglandin produced by PDGF was characterized as prostacyclin (PGI(2)). PDGF-BB increased arachidonic acid (AA) release, which, similarly to cAMP accumulation, was abolished in the presence of AACOCF3, a cytosolic PLA(2) inhibitor, and in the absence of Ca2+. U-73122, a potent inhibitor of PLC activity, blocked both the production of inositol phosphates and the AA release triggered by PDGF-BB. Extracellular signal-regulated kinases (ERKs) 1 and 2 are expressed in myometrial cells, and PDGF-BB selectively activated ERK2. PD98059, an inhibitor of the ERK-activating kinase, blocked PDGF-BB-mediated ERK2 activation, AA release, and cAMP production. The results demonstrate that PDGF-BB stimulated cAMP formation through both PLC activation and ERK-dependent AA release and PGI(2) biosynthesis. PDGF-BB also increased cell proliferation and [H-3]thymidine incorporation. This was abolished by PD98059, demonstrating that the ERK cascade is required for the mitogenic effect of PDGF-BB. Forskolin, which potentiated the cAMP response to PDGF-BB, attenuated both DNA synthesis and ERK activation triggered by PDGF-BB, suggesting the presence of a negative feedback regulation.
引用
收藏
页码:496 / 506
页数:11
相关论文
共 43 条
  • [1] PD-098059 IS A SPECIFIC INHIBITOR OF THE ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE IN-VITRO AND IN-VIVO
    ALESSI, DR
    CUENDA, A
    COHEN, P
    DUDLEY, DT
    SALTIEL, AR
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (46) : 27489 - 27494
  • [2] GRP-PREFERRING BOMBESIN RECEPTORS INCREASE GENERATION OF INOSITOL PHOSPHATES AND TENSION IN RAT MYOMETRIUM
    AMIOT, F
    LEIBER, D
    MARC, S
    HARBON, S
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 265 (06): : C1579 - C1587
  • [3] BARTOLI F, 1994, J BIOL CHEM, V269, P15625
  • [4] STIMULATION OF DNA-SYNTHESIS IN RAT UTERINE CELLS BY GROWTH-FACTORS AND UTERINE EXTRACTS
    BECK, CA
    GARNER, CW
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1992, 84 (1-2) : 109 - 118
  • [5] ANALYSIS OF MESSENGER-RIBONUCLEIC-ACID AND PROTEIN FOR THE LIGANDS AND RECEPTORS OF THE PLATELET-DERIVED GROWTH-FACTOR SIGNALING PATHWAY IN THE PLACENTA, EXTRAEMBRYONIC MEMBRANES, AND UTERUS DURING THE LATTER HALF OF MURINE GESTATION
    BIDWELL, MC
    EITZMAN, BA
    WALMER, DK
    MCLACHLAN, JA
    GRAY, KD
    [J]. ENDOCRINOLOGY, 1995, 136 (11) : 5189 - 5201
  • [6] Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry
    Brunet, A
    Roux, D
    Lenormand, P
    Dowd, S
    Keyse, S
    Pouysségur, J
    [J]. EMBO JOURNAL, 1999, 18 (03) : 664 - 674
  • [7] INHIBITION BY CAMP OF RAS-DEPENDENT ACTIVATION OF RAF
    COOK, SJ
    MCCORMICK, F
    [J]. SCIENCE, 1993, 262 (5136) : 1069 - 1072
  • [8] DAVIS RJ, 1993, J BIOL CHEM, V268, P14553
  • [9] DOKHAC L, 1986, J PHARMACOL EXP THER, V239, P236
  • [10] DOKHAC L, 1994, MOL PHARMACOL, V46, P485